Sara2

[Sara’s Story #2] “I should be studying. But I am questioning if I have a future in medicine. Will a common manifestation like cognitive decline prevent me from studying? Will my young patients be afraid of my arm crutches? No! I am not going to think this way. I need to remain positive.

So, I go online: researching MS and its treatment option. Relapses can be nearly halted. MS doesn’t automatically mean progression. I am going to tell my doctor that I want something that will let me continue to go to medical school with confidence … because any slip unacceptable. I will do whatever I can to fight back. That’s why I am going to ask about newly approved PRODUCT X.” Only PRODUCT X has been proven to deliver near-complete suppression of subclinical (MRI) activity with superior clinical outcomes versus high-dose IFN β-1a in two identical 2-year trials. Across both trials, PRODUCT X…  Demonstrated near-complete suppression of T1 Gd+ lesions  Reduced relapse rates by nearly half and the risk of disability progression by 40% Should helping Sara include a switch to a higher-efficacy earlier in the course of her disease? Think about your past experiences with other high efficacy therapies. Based on past experiences, are you more comfortable waiting and seeing how her MS goes?

Now, think about this—PRODUCT X demonstrated a favourable safety profile that allows you to intervene earlier in the course of disease. It is also dosed every 6 months with no routine JCV, cardiovascular or lymphocyte testing.

With the efficacy and favourable safety of PRODUCT X, how could intervening earlier in the course of Sara’s disease be a bad decision?

For Sara’s future, start PRODUCT X now.